These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 35226393)

  • 1. Characterizing acute and postsurgical pain management in patients receiving buprenorphine or buprenorphine/naloxone.
    Jones AC; Tillman F; Kahlon C; Seys R; Pepin M
    J Am Pharm Assoc (2003); 2024; 64(3):102035. PubMed ID: 38364887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing - a case series.
    Brar R; Fairbairn N; Sutherland C; Nolan S
    Drug Alcohol Rev; 2020 Jul; 39(5):588-594. PubMed ID: 32657496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial.
    Hassan AN; Bozinoff N; Jutras-Aswad D; Socias ME; Stewart SH; Lim R; Le Foll B;
    J Addict Med; 2023 Jan-Feb 01; 17(1):e49-e56. PubMed ID: 35916430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy.
    Moryl N; Filkins A; Griffo Y; Malhotra V; Jain RH; Frierson E; Inturrisi C
    J Opioid Manag; 2020; 16(2):111-118. PubMed ID: 32329886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel modeling of pain and depression in prediction of relapse during buprenorphine and naloxone treatment: A finite mixture model.
    Vest NA; McPherson S; Burns GL; Tragesser S
    Drug Alcohol Depend; 2020 Apr; 209():107940. PubMed ID: 32135429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interest in using buprenorphine-naloxone among a prospective cohort of street-involved young people in Vancouver, Canada.
    Pilarinos A; Bingham B; Kwa Y; Joe R; Grant C; Fast D; Buxton JA; DeBeck K
    J Subst Use Addict Treat; 2023 May; 148():209005. PubMed ID: 36921770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute pain service reduces barriers to buprenorphine/naloxone initiation by using regional anesthesia techniques.
    Seol A; Chan J; Micham B; Ye Y; Mariano ER; Harrison TK; Hunter OO
    Reg Anesth Pain Med; 2023 Aug; 48(8):425-427. PubMed ID: 36792313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' experiences with continuation or discontinuation of buprenorphine before painful procedures: A brief report.
    Hathaway DB; Bhat JA; Twark C; Rodriguez C; Suzuki J
    Am J Addict; 2023 Jul; 32(4):410-414. PubMed ID: 36850041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach.
    Ettienne EB; Chapman E; Maneno M; Ofoegbu A; Wilson B; Settles-Reaves B; Clarke M; Dunston G; Rosenblatt K
    Addict Behav Rep; 2017 Dec; 6():8-14. PubMed ID: 29450233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-specific clinical outcomes in patients with opioid use disorder treated with 24-32 mg/day of buprenorphine.
    D'Agata Mount J; Sun J; Davis A; Cover A; Sun L; Gannon C; Derenoncourt M; Garrett G; Eyasu R; Ebah E; Bijole P; Greenblatt A; Kattakuzhy S; Rosenthal E
    Addiction; 2024 Jul; ():. PubMed ID: 38978176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should emergency departments be prescribing buprenorphine/naloxone?
    Bhat C; Zworth M; Rosenberg H
    CJEM; 2023 Oct; 25(10):787-788. PubMed ID: 37805957
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute Pain Management for Patients Maintained on Sublingual Buprenorphine as Medication for Opioid Use Disorder.
    Haines AJ; Wood KC; Costello JL; Tawil T
    J Addict Med; 2023 Nov-Dec 01; 17(6):662-669. PubMed ID: 37934527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series.
    Cedeño E; Cruz A; Cortés J; Melin K; Roman L; Gonzalez A; Duconge J; Santiago D
    Patient Prefer Adherence; 2022; 16():69-78. PubMed ID: 35046643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IMPOWR Network Divided or Single Exposure Study (DOSE) Protocol: A Randomized Controlled Comparison of Once Versus Split Dosing of Methadone for the Treatment of Comorbid Chronic Pain and Opioid Use Disorder.
    McKendrick G; Davis W; Sklar M; Brown N; Pattillo E; Finan PH; Antoine D; Walters V; Dunn KE
    Subst Use Addctn J; 2024 Mar; ():29767342241239167. PubMed ID: 38528704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine-naloxone in chronic pain: Overcoming stigma for safer opioid management.
    Steenhof N; Ng K
    Can Pharm J (Ott); 2024; 157(1):7-9. PubMed ID: 38125637
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes associated with once-daily versus multiple-daily dosing of buprenorphine/naloxone for opioid use disorder.
    Allen SM; Nichols TA; Fawcett J; Lin S
    Am J Addict; 2022 May; 31(3):173-179. PubMed ID: 35226393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of opioid use disorder treatment outcomes in patients receiving split daily versus once daily dosing of buprenorphine-naloxone.
    Borris JB; Dowd-Green C; Bowman LA; Nesbit SA; Fingerhood M; Stewart RW
    J Subst Use Addict Treat; 2024 Jan; 156():209209. PubMed ID: 37939905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.